Chemotherapeutic options for the treatment of human trichomoniasis.
Antiprotozoal Agents
/ therapeutic use
Drug Resistance
/ genetics
Female
Humans
Iridaceae
/ chemistry
Lamiaceae
/ chemistry
Metronidazole
/ therapeutic use
Nifuratel
/ therapeutic use
Plant Extracts
/ pharmacology
Sexually Transmitted Diseases
/ drug therapy
Trichomonas Vaginitis
/ drug therapy
Trichomonas vaginalis
/ drug effects
Drugs
Metronidazole resistance
STD
Trichomonas vaginalis
Trichomoniasis
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
25
05
2018
revised:
11
10
2018
accepted:
20
10
2018
pubmed:
8
1
2019
medline:
17
5
2019
entrez:
8
1
2019
Statut:
ppublish
Résumé
Trichomonas vaginalis is the causative agent of the most common non-viral sexually transmitted disease worldwide. The infection may be associated with severe complications, including infertility, preterm labour, cancer and an increased risk of human immunodeficiency virus (HIV) transmission. Treatment remains almost exclusively based on 5-nitroimidazoles, but resistance is on the rise. This article provides an overview of clinically evaluated systemic and topical treatment options for human trichomoniasis and summarises the current state of knowledge on various herbal, semisynthetic and synthetic compounds evaluated for their anti-Trichomonas efficacy in vitro.
Identifiants
pubmed: 30612993
pii: S0924-8579(18)30308-X
doi: 10.1016/j.ijantimicag.2018.10.016
pii:
doi:
Substances chimiques
Antiprotozoal Agents
0
Plant Extracts
0
Metronidazole
140QMO216E
Nifuratel
U60U6P08SP
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
116-127Informations de copyright
Copyright © 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.